Merck KGaA (MRK) Earnings Call Transcript & Summary
May 13, 2026
Earnings Call Speaker Segments
Operator
operatorGood day, ladies and gentlemen, and welcome to the Merck investor and analyst conference call covering the first quarter of 2026. I'd like to remind everyone that all participants will be in listen-only mode for this session. At this point I'll pass things over to Florian Schroeher, our Head of Investor Relations, who will guide you through the conference. Please go ahead, sir.
Florian Schroeher
executiveThanks, Sarah. We really appreciate everyone being with us on this Q1 2026 earnings call. I'm Florian Schroeher, Head of Investor Relations at Merck. I'm very glad to have with me Kai Beckmann, our Group CEO, and Helene von Roeder, Group CFO. Kai and Helene are going to take us through the main slides and the financial highlights from the quarter just ended. Kai will also use the chance to give an update on where the company's strategy is heading. For the Q&A portion, we'll be joined as well by Jean-Charles Wirth, CEO of Life Science; Danny Bar-Zohar, CEO of Healthcare; and Benjamin Hein, CEO of Electronics. After that long introduction, I'll hand things to Kai to get us going.
Kai Beckmann
executiveThanks, Florian, for that introduction, and welcome everyone to our Q1 earnings call. Let's turn to slide 5. If I had to describe this quarter, I'd say it was a solid start to 2026 in spite of global challenges. Group sales organically rose by +2.9%, while EBITDA pre climbed +5.3%. Life Science and Electronics posted robust organic sales growth of +8% and +4% respectively, more than offsetting a moderate decline in Healthcare. Now I'd like to point out the remarkable performance in Process Solutions, which delivered double-digit growth of +16% in the quarter. For the first time since Q1 2023, Process Solutions reported more than €1 billion of sales in a single quarter. Healthcare's organic decline of -3% was mainly driven by generic competition for MAVENCLAD in the US. Beyond that, we saw a solid contribution from our rare disease franchise, with a +4% portfolio effect. Turning to Electronics, which showed positive organic sales development in Q1, this was driven by double-digit growth in Semiconductor Materials. The overall solid start to the year and the particularly strong finish to the quarter led us to raise our guidance for full year 2026. You may also recall that we guided just one week after the crisis in Middle East broke loose.
Kai Beckmann
executiveSince that time, we've gotten a clearer read on the macro developments, so today's update to our 2026 guidance reflects those changes. Also, our shareholders approved the dividend proposal of €2.2 per share at the AGM on April 24. Turning to slide 6, you'll see an overview of how each business sector performed. Life Science contributed the most, posting organic sales growth of +8.3%. Every one of the three business units in Life Science delivered organic growth, with Process Solutions leading the way — it saw a clear acceleration in growth toward the end of the quarter, producing a growth rate well north of the roughly 10% average mid-term aspiration. Discovery Solutions and Advanced Solutions came in as planned. Healthcare recorded an organic sales decline of -3.4%, caused by the expected drop in MAVENCLAD amid generic competition in the US. Still, I want to call out CM&E, which showed continued resilience along with continued double-digit growth of PERGOVERIS. Electronics rose +4.2% organically, with our semiconductor business up on the back of double-digit growth of the Semiconductor Materials franchise. Now to the right side of the slide: EBITDA pre rose +5.3% organically compared with the same quarter a year ago. FX headwinds had a negative impact of -5.7%.
Kai Beckmann
executiveKeep in mind, please, that during Q1 we experienced a currency headwind that was disproportionate compared with what we had anticipated for the whole year. As we noted on our Q4 earnings call, EBITDA pre in Q1 benefited from two one-off effects. The first was the divestment of our OLED IP portfolio to Universal Display Corporation, which produced a gain of €42 million in Electronics. Second, we had indicated that a possible cost recovery might be incurred in connection with a supplier mislabeling dispute unrelated to product quality. I am pleased to confirm that this matter has now been successfully closed, generating an additional gain of €25 million in Electronics. With that, I will hand things over to Helene, who will review our financials in more detail.
Helene von Roeder
executiveThanks so much, Kai, and a warm welcome from me as well. I'm turning to slide 8 now, which gives an overview of our key figures for the first quarter. Net sales on a reported basis declined -2.8% to €5.134 billion. Organic growth came in at 3%, but as we guided on our last earnings call, that was offset by outsized FX headwinds this quarter, particularly from US and Asian currencies. We do expect that impact to lessen as the year progresses. Reported EBITDA pre dropped -0.3% to €1.530 billion. On an organic basis, though, EBITDA pre rose 5%, powered by Life Science along with two one-offs in Electronics, as Kai just noted. The EBITDA pre margin was up 70 basis points year-on-year at 29.8%, while the underlying margin stayed roughly flat. EPS pre followed a similar pattern to EBITDA pre, coming in at €2.11 per share versus €2.12 per share in Q1 '25, helped as well by financing cost that came in below what we had anticipated. That trend leads us to assume the midpoint of our financial result in 2026 will be €10 million better than what we guided in March. Operating cash flow climbed sharply, up 47.2% to €880 million, reflecting movements in other assets and liabilities. You heard Kai speak about momentum in Life Science picking up toward the end of the quarter.
Helene von Roeder
executiveSpecifically, this affected how our working capital developed as of March 31. To help support growth ahead, we maintained elevated inventory levels. Meanwhile, trade accounts receivable rose considerably, tied to the sharp jump in sales at the close of the quarter. Net financial debt declined modestly, by -3.5%, to €8.318 billion versus the end of December last year, mainly thanks to robust operating cash flow and disciplined CapEx. I'll now walk through our three businesses in detail, beginning with Life Science. This quarter marks the first time we report under a new organizational structure and our recently implemented go-to-market strategy. As a reminder, Process Solutions keeps the same scope, whereas Advanced Solutions now includes our lab water, diagnostics and regulated materials, biomonitoring, contract testing, and contract development and manufacturing services businesses. Discovery Solutions, our third unit, brings together our chemistry and biology franchises. Life Science sales rose organically 8.3% in Q1, driven by an acceleration in Process Solutions, backed by solid underlying demand for downstream processing and single-use solutions near the end of the quarter, together with limited customer safety stock buildup and new customer projects.
Helene von Roeder
executiveSales were solid in Q1, and order intake was strong once again — book-to-bill also remained comfortably above 1. Since we completed the JSR acquisition on April 1st, our downstream business will offer a wider portfolio starting in Q2. With this deal, we gain advanced Protein A chromatography capabilities, which strengthens our capacity to deliver protein purification solutions that are more efficient and scalable, supporting faster biopharmaceutical production. Turning to Discovery Solutions: organic sales rose 1.6% versus a low comparable base, despite persistent headwinds from subdued spending across academia and government as well as a shifting market environment in China. In Advanced Solutions, organic sales grew 4% in a market that is gradually improving, led by industrial testing and large pharma customers. EBITDA pre increased 7.4% organically in Q1, and the EBITDA pre margin improved 50 basis points year-over-year, mainly on volumes in Process Solutions. M&S and admin spending stayed roughly flat, which reflects cost discipline, while R&D expense rose as planned to secure continued future growth and differentiation. Now moving to slide 10, where I'll share details on developments in our Healthcare business. Healthcare posted an organic sales decline of -3.4% in Q1, which is ahead of the indication we gave on the Q4 earnings call.
Helene von Roeder
executiveThe primary drivers are US sales of MAVENCLAD along with favorable phasing in China. Looking at the franchises, rare diseases contributed the most to growth, which includes a 4.4 percentage point contribution from SpringWorks plus initial revenue from a promising launch of pimicotinib in China. As we mentioned on our March call, Ogsiveo and Gomekli sales came in sequentially lower given US stocking effects. CM&E delivered a modest organic gain of 1.2% against difficult comparables. That's helped by favorable phasing in China, as noted earlier, and partly offset by unfavorable phasing in the Middle East. Fertility fell -5.2% organically in Q1, driven largely by lingering pricing headwinds for Gonal-f in the US. Those mostly annualize in Q2, which suggests Gonal-f's trajectory ought to improve toward roughly stable for the rest of the year. PERGOVERIS, by contrast, kept up its very strong growth, rising 20% organically in Q2, and we remain focused on preparing for its US launch in H2. Oncology sales declined -4.9%, chiefly reflecting competitive pressure on ERBITUX and BAVENCIO. N&I was down -9.2% amid ongoing erosion of Rebif consistent with the interferon market and generic competition for MAVENCLAD in the US. The MAVENCLAD business outside the US grew at a double-digit rate. A brief note on our pipeline before I move to margins.
Helene von Roeder
executiveIn April, we announced that the first patient had been dosed in our Phase 3 enpatoran program, which builds on encouraging Phase 2 data. The Ellouence? studies are assessing enpatoran in lupus rash patients who have an active skin manifestation. Now turning to profitability: EBITDA pre fell -8% organically. That is a better result than the organic sales decline, even with significantly higher R&D, which implies swift execution on cost measures. However, when we factor in slight dilution from SpringWorks and significant FX headwinds, the EBITDA pre margin came in at a very healthy 35%. On the basis of our updated guidance, which Kai will present in a minute, we still expect lower margins for the rest of the year amid lower US MAVENCLAD sales and launch investments, such as those for pimicotinib and for PERGOVERIS. Moving on to Electronics on slide 11: organically, sales rose by 4.2% in Q1, while currency headwinds of -7.5% were most pronounced in this segment, and a portfolio effect of -10.6% from the divestment of Surface Solutions led to a decline in reported sales of -13.9%. The solid organic growth was driven by strong performance in our Semiconductor Solutions business, which grew organically by 7.5%, fueled by continued growth in semi materials at low double-digit organic growth rates.
Helene von Roeder
executiveAI is still fueling solid growth, and so are advanced nodes plus specialty and mature nodes across Asia. In Q1, our DS&S business came in as we expected, with sales leveling off from one quarter to the next. At Optronics, the Q1 trend matches what we pointed to on our previous quarterly call. To bolster our metrology and inspection position, we recently launched a new site close to Grenoble, growing production capacity for tools that let customers build the next generation of AI chips. Turning to profitability, EBITDA pre rose sharply, up 30.1% organically, and the EBITDA pre margin came in at 34.6% despite substantial currency headwinds and favorable portfolio effects. Worth noting: the EBITDA pre margin was lifted considerably by one-off items amounting to €68 million, tied to the sale of the OLED IP portfolio to UDC and to cost recovery linked to a supplier mislabeling dispute involving non-quality. Before I hand things back to Kai, let me also touch briefly on our balance sheet and cash flow. On slide 12 you can see that our balance sheet grew by €1.6 billion versus the end of December '25. It went from €51.5 billion to €53.1 billion — a rise of more than €1.1 billion — driven by higher net equity from profit after tax of €669 million and an OCI increase of more than €550 million.
Helene von Roeder
executiveOur equity ratio is holding steady at 56%. Now, if we look at the key movements on the asset side, keep in mind this is a comparison against December 2025. Receivables rose from €3.9 billion to €4.3 billion, and that was driven by FX effects along with a strong sales performance nearer the end of the quarter. Inventories came in slightly higher, moving from €4.6 billion to €4.8 billion, mostly because of FX effects. Goodwill and other intangible assets went up from €25.6 billion to €26 billion, while other assets rose from €4.7 billion to €5.1 billion, with both increases mainly attributable to FX effects. Turning to the last slide in the financial section, here's the year-over-year comparison of cash flows. Operating cash flow rose significantly, from €556 million in Q1 '25 to €880 million in Q1 2026, even though profit after tax declined. Changes in other assets and liabilities turned positive, contributing €30 million versus -€224 million in Q1 '25, thanks to higher deferred income for goods in transit and increased bond interest accruals. Changes in working capital improved by €75 million year-on-year, reaching -€322 million. Investing cash flow increased significantly to €-750 million from €419 million in Q1 '25, a change of €336 million driven by the short-term investments and payment from the acquisition of JSR Chromatography.
Helene von Roeder
executiveFinancing cash flow showed a major improvement, moving from -€1.6 billion in Q1 '25 to -€62 million in Q1 2026, since the prior-year financing cash flow had included repayment of €1.5 billion of US dollar denominated bonds. That said, I'll now return the floor to Kai for the outlook.
Kai Beckmann
executiveThanks, Helene. Moving to slide 15, we'll walk you through the guidance we've raised. You heard my opening remarks about improved visibility after steering through another two months of volatility and the solid momentum we keep generating throughout our businesses. On that basis, we're revising the 2026 target corridor for the group, and we now anticipate €20.4 billion to €21.4 billion in sales, with EBITDA pre between €5.7 billion and €6.1 billion. Most of that change stems from how we're modeling stronger momentum in our Life Science business and Healthcare holding up well despite a tough environment. Consequently, the implied corridor for organic growth of group sales shifts to 0% to +3%, versus -1% to +2% before. Our guided FX impact on sales, previously -4% to -2%, is now projected at -3% to -1%. The group EBITDA pre organic growth rate is now anticipated in a range of -2% to +2%, compared with -4% to +1% previously. The expected FX impact on EBITDA pre has been revised to -5% to -2%, improved from -7% to -3% before. EPS pre guidance now stands at €7.50 to €8.20 per share, up from the earlier €7.10 to €8 range.
Kai Beckmann
executiveTo give you a bit more detail by business sector, let's turn to slide 16. Beginning with Life Science, we're raising the corridor for our organic sales growth guidance, which now comes out to +4% to +7%, compared with +3% to +6% before. The driver behind this is the strong performance turned in by our Process Solutions business at the close of the quarter. As for Advanced and Discovery Solutions, our underlying assumptions remain the same. We expect market conditions in biotech funding to improve and academic research to stabilize, while we work through a shifting market environment in China. We now anticipate EBITDA pre delivering an organic increase of between +4% and +8%, versus +2% to +6% previously. Turning to Healthcare, we are lifting our organic sales growth guidance by 1 percentage point, to -6% to -3%, which mainly reflects two additional months of US MAVENCLAD sales. As a result, we're also raising our organic EBITDA pre guidance, giving -12% to -8%, compared with -14% to -10% previously. On MAVENCLAD US, please keep in mind that our forecasting methodology has not changed. We factor in what is in the books and take a conservative view on the rest of the year. There could be some near-term upside to that assumption. That said, visibility beyond the next couple of weeks is limited, given additional generic entries.
Kai Beckmann
executiveCompared with Q1, organic growth in Q2 should be softer because of phasing effects and a likely smaller contribution from MAVENCLAD, while in H2 SpringWorks will start contributing to organic growth. Also, as we keep working to streamline our Healthcare business, we are reshaping the franchise into four therapeutic areas so that our product offering lines up with the commercial capabilities needed. Those four TAs are rare diseases, cardiometabolic, fertility and endocrinology, and specialty care. That last one combines oncology and N&I. We will report under the new structure starting in Q2, and to help with your modeling, we will share historical figures for the new structure with you in due course. For Electronics, we confirm our organic sales guidance and EBITDA pre growth projections, including the ranges within that guidance. To sum up, Q1 was a solid start to the year in a challenging environment. Through disciplined execution, we captured opportunities across our portfolio. Although macro conditions remain demanding, we now have greater clarity on the actions we will take and the markets we can win. Our updated guidance reflects these assumptions. With that, let me zoom out now and give you my initial views on where the Merck Group is headed strategically going forward.
Kai Beckmann
executiveMerck is functioning from a strong foundation. We hold a strategic position across growth markets spanning the lab all the way to customers and patients, and we operate throughout the whole value chain within the broader life science spectrum. Our know-how in biology, chemistry, and physics, paired with our distinctive standing as an enabler and a user of AI at the same time, provides a robust basis for driving next-gen innovation. We see that customer and patient needs are shifting. The sweeping technological transformation is speeding up. Digital and physical realms are merging, propelled by artificial intelligence. AI greatly speeds discovery and early-stage R&D, cutting the time needed to pinpoint promising drugs, materials, and biologic candidates. As innovation cycles tighten, competitive advantage moves downstream toward companies able to swiftly validate, manufacture, scale, and commercialize innovations. Given this backdrop, Merck holds a unique position to lead through our diverse portfolio and our inherent capabilities. How will we address that? To capture the most from these opportunities, I'm outlining our new strategic direction. It is built to create superior value for customers and patients and, in turn, to deliver stronger structural growth at attractive margins for Merck. Specifically, we will draw on four streams, which I will return to shortly.
Kai Beckmann
executiveIn the end, we're going to adapt what we offer along vertical lines, and beyond that, bundle and integrate the capabilities we have. Put simply, where it counts, we'll optimize for speed and scalability by drawing on our distinctive footprint. That said, our commitment to the mid-term guidance we gave you at last year's Capital Markets Day remains firm. Through 4 strategic streams, we intend to unlock growth and value creation. This will help lift our company toward greater speed and improved scaling. For our strategy to be implemented, scaling will be essential. First, our focus goes to high-growth value drivers. We stay disciplined in how we manage the portfolio, putting priority on the products and businesses that produce the greatest value. Second, we'll move selected product portfolios toward integrated workflow solutions. That is, we expand from stand-alone products to integrated end-to-end solutions, where we can address high-value customer problems and build on expertise we already have. Third, we'll draw on platform capabilities across businesses. We will pinpoint capabilities to integrate and platform across the enterprise, which lets us support all businesses better and improve our agility, speed, and scale. Fourth, innovation will be sourced and scaled through M&A and in-licensing. For every business, we regard M&A as a growth lever, clearly aligned with high-growth value drivers.
Kai Beckmann
executiveFirst and foremost, we'll roll out those 4 pillars gradually, anticipating that their financial effect will show up step by step as we back our mid-term guidance. In certain high-value markets — I'm now on page 20 — we'll leverage deep expertise spanning everything from stand-alone products to integrated end-to-end offerings. Across a range of areas, we're seeing a shift toward greater demand for solutions that span different portions of the value chain, including materials, consumables, equipment, tools, software, and services. Solving our customers' problems requires this, and we refer to it as integrated workflow solutions. To meet those more integrated requirements, we also need to operate in a more integrated manner within our own company. That's what we call platform capabilities. Take AI deployment, post-merger integration, carve-outs, and an integrated management systems approach we intend to build, for instance. Although this represents a strategic direction spanning not only the mid term but the long term as well, it's a significant journey we're embarking on. We aren't beginning from zero. Allow me to point to 2 of our highly successful examples in bioprocessing and heterogeneous integration. In bioprocessing, we've already achieved substantial progress toward becoming a provider of integrated workflow solutions, pairing consumables such as our bags with instruments such as our bioreactors, supporting processing steps across multiple critical control points, and governed by software products such as our PAT solution.
Kai Beckmann
executiveWhen it comes to the rapidly expanding field of heterogeneous integration for advanced semiconductors, we pair our advanced materials with tools such as metrology and inspection, giving customers a more integrated offering. Now, on page 21, it will come as no surprise that we'll use inorganic moves to put money into the opportunities lying ahead of us. M&A has always been, and still is, a vital element, and we intend to widen the scope of our M&A. That said, we'll stay disciplined, consistent with our strategic direction. Most importantly, we will optimize the portfolio right across the group, aligning it with the high-growth value drivers we've identified. M&A will likewise play a key part when it comes to programmatic innovation. That means targeted transactions that sharpen our product offering and speed up our integrated solutions approach, and we might also branch into opportunities that nurture our internal capabilities. Next, we'll pursue external innovation to build a risk-balanced pharma pipeline, reinforcing early- and mid-stage development. We are committed to running Healthcare above a 30% EBITDA pre margin, with an R&D-to-sales ratio heading toward 25% over the mid-term. Our financial criteria stay the same: IRR above WACC, EPS pre accretion after synergies, and a strong investment-grade rating at all times. Now, on slide 22, the Executive Board and I feel confident about the path we're on.
Kai Beckmann
executiveOur strategic course rests on a solid base—linking what we do well and spotting fresh avenues for growth. Merging our fundamental expertise across biology, chemistry, and physics with data and AI will make us a nimbler business capable of delivering faster and at larger scale. That's the way we'll serve customers and patients best. There's enormous potential at Merck, and an exciting road lies before us to unlock more of it. Now is the moment to get to work. We'll keep updating you as things progress, and at present we foresee a dedicated stand-alone event sometime next year. I hope your enthusiasm matches ours for what's ahead. With that said, Florian, over to you now to get us started on Q&A.
Florian Schroeher
executiveThanks a lot, Kai. Just before we proceed, one small clarification regarding Q1: in Electronics, we recorded a negative portfolio effect. With that said, I'll turn things back to Sarah so she can moderate the Q&A portion.
Operator
operatorThanks. We’re moving into the question-and-answer portion now. If you’d like to ask our speakers something, dial *11 on your phone keypad at this point to join the queue. After your name is called, you’ll be able to pose your question. If you’re on speaker equipment today, please pick up the handset before you make your selection. Just a moment while we take the first question. Today’s first question comes from Richard Vosser at JPMorgan. Please go ahead.
Richard Vosser
analystHi, thank you for taking my questions. First question, please, on Process Solutions. Could you provide a little more detail on the growth in the quarter on an underlying basis? What was the safety stock build, and what was the fill of the customer warehouse? Related to that, how should we think about that business going forward? Would you expect a quick reversal of some of those elements on the safety stock, or would you expect this to persist given the uncertainty in the geopolitical environment? Your thoughts on the underlying business, which does seem very, very strong as well. Just your thoughts on that going forward. Then second question, just on the strategic elements that you've just highlighted, Kai. M&A clearly a key driver. It does seem like the elements around the healthcare pipeline have taken a sort of a higher level within the thoughts in terms of M&A. Is that right, or should we think of it as more balanced across the group? How should we think about business development going forward? Thanks very much.
Jean-Charles Wirth
executiveThank you, Richard. This is Jean-Charles. I'll take the first question. Broadly speaking, three effects shaped Process Solution's Q1 performance. First, let me highlight the operational efficiency gain, whose impact came in stronger than we had expected. Improved inventory management and fill rates drove it, enhancing the customer experience tied to our new go-to-market model. As you may recall, I presented that new go-to-market model, under which we want our business to operate in close alignment with our supply chain and manufacturing capabilities, and right now those efforts are paying off. The second key driver concerns the contributions from new customer projects in this quarter, which lifted results thanks to those customers' strong performance in their molecules, along with an effect from stocking at a new warehouse. Lastly, the third driver has to do with the fact that we saw stronger buying patterns, especially from an APAC customer, which may partly be linked to the global crisis advancing in March. Setting this effect aside, we would still land nearer the top of the 8% to 12% range that we discussed at last year's Capital Market Day and on the March conference call. Although certain of these exceptional Q1 effects could carry into Q2, their impact should prove less pronounced as we move through the second half of the year, bringing us back to an anticipated normalized average underlying growth rate of around 10% going forward.
Jean-Charles Wirth
executiveTo directly address your question about the underlying business, that business is very solid. Our order book is quite solid and strong. As Helene mentioned earlier, our book-to-bill ratio is far above 1. One last comment from me: if you consider our mid-term guidance, our mid-term guidance for Process Solution remains unchanged, at around 10%.
Kai Beckmann
executiveRichard, I’ll address the M&A question. To begin with Healthcare: as I said in my remarks, Healthcare is going to be run at an EBITDA pre margin above 30%. That makes it accretive to margins at the group level, and our emphasis will be on building a stronger pipeline, mainly in the early- and mid-stage portion. There, external innovation is what we’ll draw on, whether through M&A or in-licensing. Now, widening the view to the group, which is the larger picture: across the group as a whole, we will put money into the opportunities in front of us that align with our strategic direction. That covers targeted transactions aimed at enhancing our product offering and speeding up the integrated solutions piece, as I noted in the speech, and we could additionally broaden into opportunities that nurture our internal capabilities. The 2 examples I cited earlier regarding bioprocessing and heterogeneous integration can provide a useful general direction. Our anchor will be what we call the broader life science value chain. That is the larger picture we have referred to.
Richard Vosser
analystPerfect. Thanks very much.
Operator
operatorThanks. Our next question is from Sachin Jain at Bank of America. Go right ahead.
Sachin Jain
analystHello, and thanks for taking my questions. I have just a couple, please. First, actually for Kai, just to clarify some of the commentary from your strategic remarks. I believe in the Healthcare comment, you mentioned R&D spend you're now targeting at 25%. I was wondering if you could comment on how quickly you get to that level. Maintaining EBITDA above 30%, I just think consensus is sort of in the 33%, 34% range. Should we think about R&D spend being downside to consensus Healthcare EBITDA margins with this sort of refocus on pipeline investments? Second, you reiterated the mid-term guide, which is very helpful. That obviously implies an acceleration from what you're guiding for '26. Would we see the underlying mid-term guide appear in '27, or is again that a bit further out? Then the final one is just for Danny, if you could just update us where you are on PERGOVERIS submission and timelines. You've obviously reiterated 2H '26, but I think on the earlier call you gave a very detailed assessment of submitting Part 2 and then a 60-day review. Wondering if you could just update us where we are on that. Thank you.
Kai Beckmann
executiveI’ll begin with the margins so this point is completely clear. We’re discussing a shift toward that 25% range for R&D so we can secure the 30% above 30% EBITDA pre margin and become accretive to group margin. Naturally, that always hinges on what we have in our hands. There’s no automatism. It hinges on which pipeline candidates we have in our hands and how much investment is required to drive these opportunities. It’s very important to keep that in mind. So ’26 will be tracking at where we are. There’s nothing specific here in addition to mention on ’26. Now let’s discuss the second part of your question regarding the guidance and how we go toward ’27. I think it’s very important to understand we have confirmed our mid-term guidance today, which was part of my speech. For 2027, Life Science and Electronics are well on track. I think there’s nothing to add for Life Science and Electronics. For Healthcare, it’s important to consider that depending on where MAVENCLAD will be for the next quarters, the more successful we are, the tougher ’27 will be. That’s pretty straightforward.
Kai Beckmann
executiveNaturally, the question that’s still unresolved is what precisely will occur with PERGOVERIS, and that will hinge, naturally, on when a potential launch takes place. With that, I’ll pass things over to Danny.
Danny Bar-Zohar
executiveThanks, Kai. Hi, Sachin. About PERGOVERIS — given the ongoing really robust organic growth of 20% and the fact that we also expect double-digit growth for the full year — when it comes to the US, to be quite frank with you, there isn't much change. That's actually good news. We keep having very constructive dialogue with the FDA and intend to file Part 2 of the file under the voucher procedure over the coming months, and that's fully consistent with our unchanged goal of launching in the second half of 2026. We'll only be in a position to say more about the US opportunity once we have clarity on the label, as I've said several times before. We're doing everything we can to bring the product to patients as soon as possible and to maximize the potential, but as for the label language, it would be difficult to discuss that now.
Sachin Jain
analystThanks.
Operator
operatorThanks. The next question today is from Peter Verdult at BNP Paribas. Please go ahead.
Peter Verdult
analystThanks. This is Peter Verdult from BNP. Kai, may I press you a bit on how quickly business development will move? Should we expect that to accelerate in 2026? And yes, thank you for the strategic update, but let me push you for some concrete examples of the immediate changes you've made to the way Merck operates day to day since you took on the Group CEO role. I'd be interested to hear what immediate changes you've made. Then secondly, Danny, on ASCO and for the remainder of the year, are there any updates — or better updates — or clinical trial starts that you want to flag for the market to keep an eye on? Thank you.
Kai Beckmann
executivePeter, I'm not entirely certain I've got your question exactly right, since the audio wasn't perfect, but on the BD side of what you asked, of course, we're constantly evaluating opportunities, and the market is becoming more attractive as we move forward. We're managing that as we go along, there's nothing to share right now, so just stay tuned on that front. Now, regarding the strategy itself, we're actually in week two. It was very important to begin our implementation work, very important that we start as quickly as possible with that implementation work, and that's why we shared the direction today. Of course, we can't share details on implementation steps at this point, since it's only week two. Stay tuned for updates on our progress. We'll keep you informed here, and of course, most importantly, toward the end of next year's event, and we'll share a much more detailed picture of how we're progressing, and of course, I'd expect some further series updates on the details. For now, that's the frame, and bear with us while we work on the details.
Danny Bar-Zohar
executiveHi, Peter. This is Danny. On the subject of clinical trial starts, you heard from Helene regarding enpatoran — two twin studies, global studies, a Phase 3 in lupus rash as a potentially first-in-class drug for this huge unmet need. We dosed the first patient. That adds to the already ongoing Phase 3 study of cladribine capsules in generalized myasthenia gravis, which is also recruiting very well. The next one to begin — and I believe we'll announce it within the next couple of weeks, no more than that — is our anti-CEACAM5 ADC, Pritol?, M9140, in a global Phase 3 study in third-line metastatic colorectal cancer, very exciting. We have additional ongoing data that will come out, very exciting, also from the pimicotinib extension study, and we recently started a bridging study to maximize the opportunity also in Japan. There is a lot of good traction from David's team.
Peter Verdult
analystThanks.
Operator
operatorThanks. Our next question comes from Matthew Weston at UBS. Go ahead, please.
Matthew Weston
analystThank you. I have two questions, please. The first one is for Danny about SpringWorks. Now that we should be getting past, I suppose, all those integration dynamics, could you take us through what investors ought to anticipate roughly quarter by quarter regarding SpringWorks growth as we head toward possible competitor launches and Merck truly realizing the full potential of the acquisition? Then the second one is for Kai. I know you've been pulled in a number of different directions, but we've seen the strategic update headlines. I understand it's quite early, and you've restated mid-term guidance, which I take to be a statement meant to reassure investors that there isn't a meaningful incremental cost attached to what you have planned. I'd love to hear how you see the new strategic thinking showing up for investors, over what timeframe, and how we will observe it. Will Merck be growing faster? Will Merck be more profitable? How will we actually measure success?
Danny Bar-Zohar
executiveHi, Matthew. Danny here, taking the SpringWorks question. I'll attempt to answer it from a few different angles. For the quarter, Q1 2026, rare disease overall — and rare disease takes in the SpringWorks legacy products, Gomekli and Ogsiveo, plus pimicotinib in China — rare disease overall came in at €94 million. As I noted last time, €93 million was attributed to Ogsiveo and Gomekli. Q1 sales declined sequentially against Q4, down €9 million. Actually, it's mostly pronounced for Ogsiveo. For Gomekli, it was rather flat. Here's the reason, and the main one, for that: stockings ahead of WAC increases, which we've minimized as we promised, if you recall the dynamics for SpringWorks last year. We minimized it as we promised. Now, if you drill down into one of the most important surrogates for launch dynamics here, with a focus on Ogsiveo, which is new patient starts, we see a healthy increase in Q1 versus Q4. The phasing that you suit towards Q4 has nothing to do with the rise in new patient starts. The launches in Germany and in Austria are, I'd say, quite encouraging. For Gomekli, we're actually working against a competitor.
Danny Bar-Zohar
executiveThat's a pretty well-established one, and the launch is going along quite nicely. If you look at the figures for the competitor's MEK inhibitor in the US, it's clear our EMD team over there is performing really well when it comes to share. And yes, you're correct that the integration is now behind us. There's plenty still to do since we're pushing ahead on many fronts: cutting down surgical procedures in line with the guidelines for both products, growing shares in systemic first-line therapy, and managing discontinuations along with drug holidays. The real-world situation for these tumors differs from a clinical trial, since patients tend to go on and off, not always because of the therapy, and we've gotten used to that too. Mostly it's about finding those patients who are under active surveillance, and we're making a lot of headway there by leveraging plenty of advanced analytics and AI to identify these patients, and I'm seeing the results. A bit more color on the number of prescribers. The number of prescribers for Ogsiveo was, I'd say, sort of flat, edging up slightly, but over the last 4 months there's a 20% increase in the number of prescribers.
Danny Bar-Zohar
executiveWhen you talk about that roughly €1 billion projection for Ogsiveo and the near-blockbuster figure for Gomekli, our view is that the potential remains. Well, we nudged the guidance up a bit for the first half, to at least €200 million across both products. A ramp-up is something we do expect in the second half. There's a plan in place for how we'll deliver it. I'm not brushing aside the challenges, but I'm seeing early signals suggesting a strong likelihood that we can get there. Now that we're fully integrated in Europe, and countries beyond Europe are picking up, overall I feel comfortable with what the market currently expects for the two products in 2026.
Kai Beckmann
executiveMatthew, thanks for asking about the strategy. Let me say it again: this strategy is a mid- to long-term direction, which I've laid out today, and it represents a fairly significant change in the way we run the group — the first part, the earlier part, supports our mid-term guidance, and then on top of that, we'll progressively see impact as we move beyond the mid-term guidance. I'd ask for your patience and for you to stay tuned for the updates we'll share in the course of next week — next year — on how we build that progression over the coming years. It's very important to understand this mid- to long-term strategy; it matters for capturing growth opportunities on the mid- and long-term horizon, and we'll share details as we go forward.
Matthew Weston
analystThanks.
Operator
operatorThanks. The following question comes from James Quigley at Goldman Sachs. You have the floor.
James Quigley
analystThanks for the opportunity — I have two, and sadly both are clarifications. On Healthcare R&D, you mentioned that reaching 20%, or the updated guidance for 25%, hinges on what's currently in the pipeline. Right now we're at roughly 20% to 21%. Is it reasonable to expect that we remain at this level until additional M&A or BD comes along, and that's what lifts us toward the 25% mark? Also, regarding the increase — what were the main decisions or key factors behind raising that R&D threshold? Would the R&D spend lean more toward discovery or toward development? My second question is on Process Solutions. Jean-Charles, you said the underlying figure would be nearer the top end of the 8% to 12% range. Slide 28 states that underlying organic growth is a bit above 10%. How do you square those remarks — your comments versus the slide? And could you give us a bit more detail on the actual impact of those three key growth drivers, or the three impacts, for Process Solutions?
James Quigley
analystSpecifically, when it comes to measuring how much the stocking by APAC customers and at the warehouse contributed to growth — presumably that APAC customer stocking could carry on into the second quarter, as you mentioned. It would be great if you could just help us understand how the growth cadence in Process Solutions might unfold across the quarters. Thank you.
Danny Bar-Zohar
executiveHi, James. Danny here. I'll handle the first question. On R&D requirements, at this point, if you look at the pipeline, it's essentially the first time we've had three Phase 3 programs running or just getting started that aren't correlated with one another, and that's a real achievement. I can't recall that happening at Merck — it's a strong testament to what we're capable of. Now, once we shift assets from Phase 2 into Phase 3, and also after we shared last time that we shut down the work in the DDR space, our mid- and early-stage pipeline is fairly thin, I'd say. We need to build that up here so we can sustain, or make sure we grow past the low- to mid-single-digit mid-term guidance we provided beyond 2030, beyond 2031, and that's something we have to begin building now. As for where we'll focus when it comes to BD, bolt-on M&As, and so forth, it'll be mainly early to mid-stage, and we're not ruling out discovery platform deals that can keep leaning on validated biology and drawing on our own strengths in conjugations and so on and so forth. That covers what we'll invest in.
Danny Bar-Zohar
executiveSo when you look at R&D ratios, we're sitting at roughly 21% at the moment. As Kai mentioned, we'd move step by step in the direction of 25%. We'll only do that while keeping EBITDA margins above 30%. This won't happen all at once. It has to come from a solid acquisition or a solid in-licensing deal that's genuinely worth putting money into. Keep that in mind. It'll be gradual. It has to feed the mid-term pipeline so we can secure the long-term future of the Healthcare business.
Jean-Charles Wirth
executiveHi, James. This is Jean-Charles. I'll give you a bit more detail. As I mentioned, three factors drove Process Solution's Q1 performance: operational efficiency tied to our new go-to-market model; the second was new customer projects, along with a stronger buying pattern, with many of these, as I noted, coming from our Asian customer. Overall, I want to restate that although these exceptional effects affected Q1, a number of them could carry into Q2. Keep that in mind when you're building your model. Then, regarding H2, we're assuming we'll get back to a somewhat more normalized underlying growth rate of roughly 10%. So, to sum up and answer your question, I have a lot of confidence in the overall underlying business for Process Solution in 2026.
James Quigley
analystThanks a lot — that’s helpful.
Operator
operatorThanks. Our following question comes from Charles Pitman-King at Barclays. You have the floor.
Charles Pitman-King
analystHey, everyone. Thanks so much for taking my question. I have two, if that's alright. First, for Jean-Charles, I appreciate all the extra detail you gave on the extraordinary items for PS. I was hoping you might expand a bit on the underlying performance overall that you still feel confident about. I'm curious whether you can comment at all on any share gains you picked up during the quarter. And on the underlying mix, first, could you confirm what your exposure is to the equipment mix? Since you mentioned a rapid gain toward the end of the quarter, I'm wondering whether renewed demand for equipment in this space is what drove the performance in 1Q — any specifics you could share would be really helpful. Then my second question is on your guidance. In your release note, you say you're assuming the Middle East conflict will de-escalate in 2Q and stabilize and normalize from there. Since your exposure to the Middle East is relatively limited, I'm wondering if you could give us a sense of any potential impact we might see, particularly for Healthcare, if that return to normalization doesn't happen?
Charles Pitman-King
analystI appreciate that.
Jean-Charles Wirth
executiveI'll begin with your first question, which was about the market share gain. We don't make comments comparing ourselves with our competitor, but on a broad level, as we've said, commenting on market share trends inside a single quarter is quite difficult. As for the underlying mix, remember that consumables make up the main part of our portfolio. Roughly 90% of our portfolio consists of consumables, with 10% being service and equipment. On your second question, about the Middle Eastern conflict, I'll pass things to Kai.
Kai Beckmann
executiveCharles, I’ll address the Middle East question. As you know, just 3% of our total sales come from the Middle East and Africa. In Healthcare, I think we’re fairly accustomed to crisis-related phasing in that region over a fairly extended period. In Life Science, I believe we’ve already noted the temporary impacts of the crisis. In Electronics, we’re likely more exposed there to consumer sentiment than other sectors are, but that has already been fully incorporated into our guidance.
Charles Pitman-King
analystThanks.
Operator
operatorThanks. Our next question is from Oliver Metzger at ODDO BHF. Please go ahead.
Oliver Metzger
analystGood afternoon, and thanks a lot for the questions. My first one concerns your strategy update. Slide 20 shows the Life Sciences value chain, and that slide implies the greatest expansion potential lies in instruments and equipment, which from an industry standpoint is underrepresented at your company. Would you agree? Can you expand further into this area organically, or is more inorganic growth really required there? That leads into my second question, since on slide 21 you lay out financial criteria for M&A, and the criteria for accretive deals are also brought down there. How do you view technology-accretive deals, which aren't necessarily earnings-accretive — and thinking about Life Sciences, earnings-accretive deals are hard to find? The last one is very quick, on Electronics, a quick calculation. The DS&S business should have been down only in the low single-digit territory, which would be a sequential improvement. Do you expect this positive trend to continue, and DS&S to turn positive already in Q2? Thank you.
Kai Beckmann
executiveOliver, thank you for that question. I’ll begin by addressing the various perspectives on the chart you referenced regarding, let’s say, how we might expand beyond materials and consumables. In certain areas we already do this, where I’ve given examples, and we plan to do so wherever it genuinely makes economic sense. There is no intention to pursue this kind of expansion across the entire portfolio into equipment and tools, but where it makes sense in order to drive growth in our core business—namely materials and consumables—and to create additional value for our customers. In those areas, we intend to do this selectively. That is the concept, which we have already demonstrated, and you recall the examples in bioprocessing or the more recent one involving Unity SC in heterogeneous integration. I think it is very important that you keep that in mind as one of the other components. Regarding the financial criteria, for larger moves, they are clearly as stated on the chart. For some smaller capability-related moves—these are more bolt-on moves—we would of course then apply a more strategic lens to that, but that is reserved only for some smaller bolt-on-related technology moves.
Kai Beckmann
executiveWe’ll deal with that when we come to it.
Benjamin Hein
executiveThanks so much. I'll take the DS&S question — this is Ben. Semiconductor Materials accounts for roughly 2/3, or 65%, of Electronics sales, and in Q1 it's again the primary engine of growth, helped by AI, advanced nodes, and sustained demand in Asia across both specialty and mature nodes. Turning to DS&S, that's approximately 15% of sales, and having bottomed out in Q4 2025, it has now stabilized quarter over quarter in Q1. Our expectation is that DS&S will be stable in 2026 and so will stop acting as a drag on growth from here on.
Oliver Metzger
analystThanks. I want to ask a quick follow-up to that last question, since the DS&S comps in H2 are really low. Sequentially, that would mean DS&S in H2 comes in worse than it did in H1. Can you confirm that, or are you viewing it as not more optimistic given the base comparison?
Benjamin Hein
executiveYou're right that the comparisons get easier, particularly as we move into H2. For the full year, our expectation is that DS&S will be roughly flat versus the prior year.
Oliver Metzger
analystI appreciate that.
Operator
operatorThanks. Our next question comes from Falko Friedrichs of Deutsche Bank. Falko, you have the floor.
Falko Friedrichs
analystThanks, and good afternoon. My first question concerns the Discovery Solutions unit in Life Sciences. What is the market situation in China doing, and how would you describe conditions in the US right now? Then, a quick second one on Advanced Solutions, where organic growth picked up nicely in Q1, and I noticed the appendix of your presentation highlights the services business as a major driver. Could you give a little more detail on precisely what was behind that, and on whether growth of this kind can hold up across the coming few quarters? Thank you.
Jean-Charles Wirth
executiveHi, Falko. This is Jean-Charles. I'll comment on both the Advanced Solution and Discovery Solution businesses. For each one, the two business units posted solid quarterly performance within the 2026 guidance. I'd describe it all as clean. We aren't seeing any exceptional effect for either Advanced Solution or Discovery Solution. Key drivers for Advanced Solution again include very strong, solid performance in what we call the quality testing business, biomonitoring, plus solid performance off a low comp when I mention business services — think CTS, think CDMO. Overall, I'd say we saw solid growth across the different franchises within Advanced Solution, with, let's say, no exceptional effect. On your question about Discovery Solution, we observed slight organic growth compared with our initial guidance, which is good. It was driven by, I'd say, low funding among US academic customers last year, if you remember correctly. If you recall last year, in March, we suffered a bit in the US from an academic segment perspective; we have a lower comp. We also benefited from an increase in our service level within the quarter for Discovery Solution, which again ties to our new go-to-market model. For Discovery Solution, you have two drivers: a lower comp in 2025, and a higher service level from a supply chain standpoint, which gave a bit of a boost to our performance, and it's aligned with our new go-to-market model.
Jean-Charles Wirth
executiveOn your question about China, with regard to Advanced Solution and Discovery Solution, we're still working our way through the shifting environment there. I'd say that overall, the market for these two business units is still soft.
Falko Friedrichs
analystAppreciate it.
Operator
operatorThanks. Our next question comes from Thibault Boutherin at Morgan Stanley. The line is yours.
Thibault Boutherin
analystThanks. I have just two short questions about pharma. First, on fertility: I believe you guided to low single-digit growth for the year. With how Q1 went, does that still look on track? And for Gonal-f specifically, once you lap the price cut taken in Q2 last year, what should we expect — stabilization, or could we see growth? That's the first one, on fertility. The second is just on CME. For CME, I think Q1 was expected to be the worst of the year, and it's actually probably better than expected. Given what we saw in Q1, could the mid-single-digit guidance for the year actually land a bit better? Thank you.
Operator
operatorSpeakers, could you please verify whether your line is muted? We aren’t hearing you.
Thibault Boutherin
analystIs my voice coming through?
Danny Bar-Zohar
executiveMy apologies.
Operator
operatorWe're able to take the next question now — thanks, Thibault.
Danny Bar-Zohar
executiveLet me begin again. This is Danny. On fertility, the main factor behind the 16% organic decline in Gonal-f is the pricing pressure that remains in the US. We implemented a substantial price reduction during the second quarter of last year, and that is still flowing through as it annualizes. That said, once this effect has annualized, we anticipate Gonal-f's momentum will strengthen considerably starting in Q2. In fact, from Q2 onward we expect Gonal-f sales to be roughly flat versus the prior year, which should also shift the overall fertility trend closer to our mid-term target of mid-single-digit growth. Naturally, being able to forecast pricing under the MFN deal will be a big help to us on that front too. Now, PERGOVERIS remains the primary growth driver for the fertility business. As I mentioned, it was another solid quarter, with sales up 20%. We are effectively capitalizing on PERGOVERIS's differentiated profile as the sole recombinant FSH and LH product. As a reminder, we recently launched PERGOVERIS in China, which is among the largest fertility markets, and we are beginning to observe some encouraging early signals from that launch. Then, of course, as we discussed for the US, our assumption is a launch in the second half of this year, supported by the priority review voucher.
Danny Bar-Zohar
executiveIf that occurs, it obviously moves us still nearer to our goal of mid-single-digit growth. Turning now to CM&E: within the CM&E franchise, we posted organic sales growth of 1.8%, yes, an increase — and that's fairly impressive given the really demanding comparison with last year, when organic growth across this whole franchise exceeded 10%. You also heard Helene mention phasing effects, and in fact there are two we want to flag: one favorable, tied to China, and the other unfavorable, linked to the geopolitical situation in the Middle East; both were roughly comparable in size at about €30 million and essentially offset one another. Going forward, we reaffirm our guidance that in 2026 CM&E ought to expand in line with its mid-term outlook of mid-single-digit organic growth. That presumes the phasing effects will wash out across the remainder of the year, as we've previously stated. For Q2, my expectation is not that CM&E returns to mid-single-digit growth just yet, but rather comes in somewhat below that, whereas the second half of 2026 ought to be well aligned with, or perhaps modestly above, the mid-single-digit mark. Kindly treat that with a grain of salt, since conditions in the Middle East remain rather volatile and phasing might differ from our present assumptions — but be assured the underlying trends for CM&E remain fully intact.
Thibault Boutherin
analystAppreciate it.
Operator
operatorThanks. Our next question comes from Rajesh Kumar at HSBC. You have the floor.
Rajesh Kumar
analystHi, good afternoon. Could I ask a follow-up about Process Solutions? You provided some quite specific quantification—or maybe not quantification—regarding color, regarding why you believe your growth is far above that of most of your other global peers: less exposure to consumables, less exposure to instruments, less exposure to China, and you also quantified that APAC buying patterns were stronger. With respect to your management systems, when you consider these quantifications, how solid is the estimate that a 2% to 3% benefit came from stocking by APAC customers? That is, how much of that is an estimate derived from the processes you improved during COVID, and how much is a known fact because you have visibility into your customer's inventory? The second follow-up question is, we are beginning the year in Process Solutions with a very high growth run rate, then we probably return to the normal 10%. I'm assuming this stocking—let's hope the stocking effect will not repeat in '27, and the world might be a slightly clearer place. Should we then expect first quarter next year to face this difficult comp, taking you to the lower end of the 8% to 12% corridor, or could it go below that corridor given the comp effect you've seen in the first quarter this year?
Jean-Charles Wirth
executiveThanks, Kumar, for those two questions. Let me attempt to address the first one regarding quantification. Yes, you're correct. I brought up the three effects, and you put out a figure of 2% to 3%. I won't comment on that. You should assume that drawing on past experience and on the new go-to-market approach, our grasp of our order book is fairly deep. I've said a number of times that we have a report known as a rainbow report, which lets us slice and dice our order intake and order book by customer, by region, and by product type. We can also look at order aging in buckets of 0 to 1 month, 1 to 3, 3 to 6, and 6 to 9. On the whole, we don't observe any abnormal pattern apart from a few customers in Asia. The quality of our insight is extremely high. One thing I'd like to emphasize beyond our quantitative reports: for several quarters now, we've been running a qualitative survey with our global strategic accounts, and we are encouraging interaction with those global strategic accounts, and I'm personally involved in some of them. Again, nothing abnormal. I want to say it again: I feel comfortable and confident about the full year for Process Solution.
Jean-Charles Wirth
executiveRegarding your follow-up question about the stocking effect for 2027, what I'd like to say is that we don't anticipate inventory normalization occurring in 2026 — perhaps in 2027 — and it will hinge on the geopolitical situation in the Middle East, and that is something we cannot predict.
Rajesh Kumar
analystThanks.
Operator
operatorThanks. Our next question comes from Simon Baker at Rothschild & Co Redburn. Go right ahead.
Simon Baker
analystAppreciate you taking my questions. I have two, please, and both concern Healthcare. First, returning to what I believe was Sachin's question regarding the gradual rise in R&D as a share of sales over time, I was wondering whether any offsetting cost reductions exist, since during the quarter, on one hand, your R&D came in above expectations, yet on the other, your control of SG&A costs was really impressive. Should we extrapolate that as a trend for the years ahead? Second, back to strategy and the framework you laid out, Kai, I am curious whether the perception of the pharma business's strengths and weaknesses has shifted at all, because if we break it into commercial and innovation, Healthcare's commercial performance across the last 15 years has been absolutely outstanding, while the R&D performance has been less stellar. Under this framework, has anything changed in how you see the strengths and the investment opportunities in pharma, given the framework and given how those two activities have performed? Thanks so much.
Danny Bar-Zohar
executiveSimon, I’ll address the margin question and the R&D ratio. You’re correct that the Q1 EBITDA pre margin remained at a very solid 35%. The year-over-year margin decline was primarily driven by FX and, to a lesser degree, by dilution from SpringWorks. Organically, we actually managed to raise the margin slightly, which is quite an accomplishment given the substantially higher R&D and the lower MAVENCLAD sales. While there was also some benefit from a few smaller one-timers that together contributed about 100 basis points to the Q1 margin, this clearly reflects our disciplined approach to cost management. As we mentioned at the start of the call, we are streamlining the organization—the entire organization—to ease pressures on some of our more mature brands such as MAVENCLAD, not only MAVENCLAD. That is what you see in the numbers. For the rest of the year, to add a bit more color, we do expect lower margins in the upcoming quarters, though still above 30%, consistent with our updated guidance. Key drivers to keep in mind here are also launch investments in rare diseases, particularly outside the US, the pimicotinib launch in China and in the US, hopefully at the end of this year, and also for PERGOVERIS when it comes—you need to balance that.
Danny Bar-Zohar
executiveThe current R&D increase, at this moment, reflects how we're ramping up the Phase 3 programs, and those are quite extensive. That's good news — we like Phase 3s. As I've said before, that continuous increase will be gradual, depending on the opportunities, up to 25%, while keeping the EBITDA margin above 30.
Kai Beckmann
executiveSimon, I’ll address the strategy question. First, I believe it’s crucial to step back and consider the group as a whole. Looking through the capability lens I’ve described to you across the group matters a great deal, and so does how every business contributes to the capabilities we require to serve customers and patients better. Starting at that level is essential, and at that level each business has a significant part to play. Now, turning specifically to pharma, we hold expertise in various areas, and we already address commercial expertise in part through our move in rare diseases and through how we apply it. Within pharma, we will remain strongly focused on risk and profitability, and on striking the right balance between the two. For pharma in particular, it’s vital to keep that in mind at all times. Once more, let me remind you that there are many opportunities if you look more broadly—what we refer to as the wider life science value chain across the different businesses—to also use AI in order to enhance how we conduct research, how we carry out manufacturing within the company, and how we generate new businesses. It’s very important to recognize that every part of our company has a significant part to play across the different businesses.
Simon Baker
analystExcellent, that’s clear. Thank you very much.
Operator
operatorThanks, and our final question this afternoon comes from Peter Spengler at DZ Bank. Peter, the floor is yours.
Peter Spengler
analystGood day, and thanks for taking my two questions. First, since you didn't give specific guidance for Q2, could you offer something like a qualitative trading update covering the second quarter? My second question: the strategic update lays out a plan for developing the portfolio and raising company velocity by leveraging capabilities across the existing businesses. While that reinforces the three-pillar structure of Life Science, Healthcare, and Electronics, did the review also consider alternative structures — for instance, a more focused two-division approach or a strategic swap of divisions? What makes the current three-sector model the optimal structure for future value creation of Merck? Thanks.
Kai Beckmann
executivePeter, I’ll begin with your second question. I believe the deck includes a chart illustrating the two ends of the spectrum we’ve been dealing with. One is what we refer to as the front end—the customer-facing, market-facing side of our businesses. I consider it essential, and it’s a competitive advantage we believe we possess: how closely aligned we are across different businesses with different customer groups and different markets. That, I think, is a strength we should build on, and those are competitive strengths when we compare them across industries. In your structure, it’s always important to keep the end customer in mind and focus predominantly on that part. At the same time, however, that should not rule out options for better collaboration across different businesses. That’s what we call building platforms, because it helps us scale better and helps us increase speed in implementation. These are the two different angles we must balance. It’s very important to keep these two extremes of the picture in mind as we examine our strategic development going forward.
Florian Schroeher
executiveWho would like to ask the opening question? Peter, could you say that first question one more time, please? Thanks.
Peter Spengler
analystCould you essentially provide us with a qualitative guidance or trading update for Q2 across the entire group?
Florian Schroeher
executiveNo, that isn’t really something we handle at the running level. On that, I hope you understand we’ll keep you posted around August.
Peter Spengler
analystThanks a lot.
Florian Schroeher
executiveThanks.
Operator
operatorThank you. I'll now turn the conference back over to Florian Schroeher for some closing remarks.
Florian Schroeher
executiveThanks a lot. I believe this has been a lengthy call and we've now hit its conclusion. So with that, I'd say we're wrapping up today's call. Many thanks, and I'll be seeing a few of you at the roadshows coming up. Thanks again, and enjoy the rest of your day. Bye-bye.
Operator
operatorThank you for joining us, everyone. That brings this call to a close. You're free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.